A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy.

Conclusion: LDR-EBRT may provide more effective PSA control at 5 years compared with HDR-EBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further. PMID: 31701035 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Radiat Oncol Source Type: research

Related Links:

For patients with unfavorable or high-risk prostate cancer, dose escalated radiation therapy leads to improved progression free survival but attempts to deliver increased dose by external beam radiation therapy (EBRT) alone can be limited by late toxicities to nearby genitourinary and gastrointestinal organs at risk. Brachytherapy is a method to deliver dose escalation in conjunction with EBRT with a potentially improved late toxicity profile and improved prostate cancer related outcomes. At least three randomized controlled trials have demonstrated improved biochemical control with the addition of either low-dose rate (LD...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. PET radiotracers targeting PSMA such as 18F-DCFPyL have shown promise in restaging men with recurrent disease post-prostatectomy but are less well characterized in the setting of radio-recurrent disease.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
AbstractProstate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to the gastrointestinal tract when treating with radiation where there is concern for the effects of inadvertent exposure of radiation to the diseased bowel. In general, management of i...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
ConclusionCombined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
ConclusionEBRT  + BT was associated with a significantly better prostate CSS compared with surgery or EBRT. EBRT alone was inferior to surgery by OS.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
To compare 10-year oncologic treatment outcomes of radical prostatectomy (RP) vs external beam radiation therapy (EBRT) vs brachytherapy (BT) for patients with intermediate risk prostate cancer (IRPC).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Whole pelvis radiotherapy (WPRT) may improve clinical outcomes over prostate-only radiotherapy (PORT)in high-risk prostate cancer patients by sterilization of micrometastatic nodal disease provided there is optimal control of the primary site.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Abstract PURPOSE: To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable intermediate risk PCa patient subgroups; GM (173) and USM (814). Differences in baseline covariates and clinical characteristics between GM and USM were analyzed using χ and Mann-Whitney test while Cox Proportional Hazards model was used to assess freedom from biochemical failure differences b...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Am J Clin Oncol Source Type: research
Conclusions: This contemporary population-based study demonstrates that approximately one third of patients with lr-pca undergo at. Patients of younger age, with less comorbidity, a higher tumour stage, higher psa, earlier year of diagnosis, and radiation oncologist consultation were more likely to undergo at. Further investigation is needed to identify strategies that could minimize overtreatment. PMID: 31548822 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
There is now clear evidence of improved biochemical disease free survival (bDFS) with radiotherapy dose-escalation in all prostate cancer (PCa) risk groups [1,2]. Despite the advent of new techniques, external beam radiotherapy (EBRT) is limited in dose escalation due to the continuous change in the position, shape and volume of the target volume as well as the organs at risk (OARs). High-dose-rate brachytherapy (HDR) is a recommended treatment of eligible patients with prostate cancer as a method of dose escalation in conjunction with external beam radiation therapy according to the American Society of Clinical Oncology&a...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Databases & Libraries | External Beam Therapy | Gastroenterology | Prostate Cancer | Statistics | Toxicology